KEY TAKEAWAY: According to the Times “If I were a Facebook executive, I might feel a Frankensteinian sense of unease these days. The company has been hit with a series of scandals that have bruised its image, enraged its critics and opened up the possibility that in its quest for global dominance, Facebook may have created something it can’t fully control.” And they want pharma to advertise more? Continue reading
KEY TAKEAWAY: Some are projecting that pharma is going to be spending more money for online ads. While I am skeptical of these projections, there are ways that pharma companies can really improve their online ad performance. Continue reading
KEY TAKEAWAY:Today’s online ads are not about getting in front of as many people as you can , they are about getting relevant ads in front of highly targeted people. This is especially true for pharma clients who are marketing specialty drugs and who don’t want their ads appearing on controversial sites. Continue reading
KEY TAKEAWAY: Never has an industry in so dire straits gone out of their way to give awards to marketing that consistently ranks at the bottom of marketing innovation. Continue reading
KEY TAKEAWAY: The chart, below, shows a health care system that is broken. When CEO salaries come in the tens of millions of dollars while patients can’t afford medications than something is clearly wrong. Continue reading
KEY TAKEAWAY: Pharma has to do a lot more to lead in digital marketing than hiring outside executives to lead the charge. To stay competitive, businesses need to adopt a team-based organizational model wherein employees can easily move between different projects and effectively shares information easily both internally and with customers. Can they do this without causing a nervous breakdown of their legal and regulatory teams? Continue reading
KEY TAKEAWAY: Janssen’s campaign for their AFIB drug Xarelto is a good one. The banner appeared in the NY Times health section which in turn leads to an in depth article on AFIB with an ad for Xarelto in the sidebar.